PassPort Technologies and Axcelead Drug Discovery Partners

  • Enter a comprehensive collaborative partnership in the field of drug discovery service using PassPort System, a new active transdermal drug delivery technology
  • Contribute to maximizing R&D pipeline value though providing a new modality

 
PassPort Technologies, Inc. (President and CEO: Tomoyuki Fujisawa, California, USA) (PPTI) and Axcelead Drug Discovery Partners Co., Ltd. (President: Yoshinori Ikeura, Fujisawa, Kanagawa) (Axcelead), here inform entering a comprehensive collaborative partnership in the field of drug discovery service using PassPort System, a new active transdermal drug delivery technology.
 
PassPort System is a new transdermal drug delivery technology that combines micro-poration technology that creates micropores on the skin surface and patch formulation technology that controls a drug absorption via micropores. By using this technology, new possibility of transdermal administration is able to be expanded for drugs that have been limited to injections and infusions.
 
Axcelead is a comprehensive non-clinical drug discovery research service provider, from discovery of drug discovery targets to optimization of drug candidate compounds, as well as a bridge process to clinical development. Currently, Axcelead is expanding its business by developing distinctive services such as an integrated drug discovery service that undertakes drug discovery research on a project basis.
 
Through this comprehensive collaboration using PassPort System, it is possible to provide an alternative transdermal drug delivery not only for low molecular weight drugs but also for other modalities such as medium molecular weight drugs such as peptides and oligonucleotides, and macromolecular biopharmaceuticals such as proteins. In addition, this collaboration will expand its application of the PassPort System to a wide range of fields such as needle-free vaccine therapeutics and cosmetics, and contribute to maximizing the R&D pipeline value for our partnering companies.
 
 
For inquiries regarding this matter, please contact the following.
 
[PassPort Technologies, Inc.]
Business Development, Jared C. Hahn
10618 Science Center Drive, San Diego, CA 92121 USA
+1-858-888-4188
E-mail: Jared.Hahn@passport-tech.com
URL: https://www.passport-tech.com
 
[Axcelead Drug Discovery Partners Inc.]
Business Planning & Operations
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
Tel:+81-466-32-4500
E-mail: info@axcelead.com
URL: https://www.axcelead.com
 
End of Document